May. 14 at 2:23 AM
Commercial-stage oncology focused biopharma Year 4/FY29 & 5-year revenues for all such bios with market caps north of
$1B & those who have reported Q126 sales & results of operations. Hence
$LEGN & TLX have been excluded.
$NVAX is also excluded because only 1 analyst provides NVAX estimates after FY28. We added gross margin multiples as well
$SNDX trades @ the 2nd lowest multiple. Remember SNDX collaboration revenues, included in revenue estimates, are 25-30% of Niktimvo sales (per SNDX mgmt) where the value comes from SNDX's 50% share. Put simplest, SNDX analyst estimates do not reflect 50% of Niktimvo sales which means, in theory, SNDX's revenue multiples are overstated.
$URGN has been on a tear. Does the relatively low multiple suggest there's more to come?
Is this the year we finally get
$IMCR data in melanoma? Remember KimmTrak may have peaked or is nearing 90% of peak at
$400MM/year
